Mitochondrial Dysfunction Induced by Sertraline, an Antidepressant Agent
Open accessThe DOI matches its Crossref record; 59 of the 63 references it cites were found in a registry or an index; 8 of the 36 sources its claims cite were checked for support.
Abstract
Sertraline, a selective serotonin reuptake inhibitor, has been used for the treatment of depression. Although it is generally considered safe, cases of sertraline-associated liver injury have been documented; however, the possible mechanism of sertraline-associated hepatotoxicity is entirely unknown. Here, we report that mitochondrial impairment may play an important role in liver injury induced by sertraline. In mitochondria isolated from rat liver, sertraline uncoupled mitochondrial oxidative phosphorylation and inhibited the activities of oxidative phosphorylation complexes I and V. Additionally, sertraline induced Ca(2+)-mediated mitochondrial permeability transition (MPT), and the induction was prevented by bongkrekic acid (BA), a specific MPT inhibitor targeting adenine nucleotide translocator (ANT), implying that the MPT induction is mediated by ANT. In freshly isolated rat primary hepatocytes, sertraline rapidly depleted cellular adenosine triphosphate (ATP) and subsequently induced lactate dehydrogenase leakage; both were attenuated by BA. Our results, including ATP depletion, induction of MPT, inhibition of mitochondrial respiration complexes, and uncoupling oxidative phosphorylation, indicate that sertraline-associated liver toxicity is possibly via mitochondrial dysfunction.
Overview
CoChat Summary
TL;DR
Sertraline caused mitochondrial dysfunction in rat liver mitochondria and primary hepatocytes, including ATP depletion, oxidative phosphorylation uncoupling, inhibition of complexes I and V, and Ca²⁺-mediated mitochondrial permeability transition via ANT. These findings suggest mitochondrial impairment may contribute to sertraline-associated liver toxicity.
Key findings
- In rat primary hepatocytes, sertraline depleted ATP early: at 37.5 µM, approximately 37%, 64%, and 90% of ATP was depleted at 0.5, 2, and 6 h, respectively; at 100 µM, nearly complete ATP depletion occurred at 0.5 h without obvious LDH release.
- Cytotoxicity followed ATP depletion: significant LDH release began at 50 µM at 2 h (~55% vs. 24% control), and at 6 and 24 h sertraline caused profound damage starting at 37.5 µM with ~77% and ~100% LDH release, respectively.
- In isolated rat liver mitochondria, sertraline uncoupled oxidative phosphorylation and inhibited complexes I and V with IC50s of 88.6 and 69.0 µM, respectively; complexes II and IV were unaffected even at 100 µM, and complex III inhibition at 100 µM was not statistically significant.
- Sertraline induced Ca²⁺-mediated mitochondrial permeability transition and inhibited ANT activity by approximately 40% at 100 µM; bongkrekic acid prevented MPT, ATP depletion, and LDH release, whereas cyclosporine A did not.
Methods
- Rat primary hepatocytes were isolated from male Sprague Dawley rats (6–8 weeks old), cultured, and treated with sertraline in DMSO at concentrations up to 100 µM; cellular ATP was measured with CellTiter-Glo and LDH release was used as a cell death measure.
- Isolated rat liver mitochondria were used to measure oxygen consumption with a Clark-type electrode using glutamate/malate or succinate, individual oxidative phosphorylation complex I–V activities, MPT by mitochondrial swelling at 540 nm in the presence of 20 µM Ca²⁺, and ANT activity spectrophotometrically.
- Data are presented as mean ± SD of at least three independent experiments; statistical significance was determined by one-way ANOVA with Dunnett’s tests or two-way ANOVA with Bonferroni’s posttest, with p < 0.05 considered significant.
Limitations
- The paper states that the sertraline concentrations used were higher than clinical concentrations; clinical Cmax after a 400 mg oral dose was ~0.74 µM, while toxic effects in this study started at 37.5 µM, close to 100-fold the reported Cmax.
- The paper states that mitochondrial impairment may not be the sole contributor to sertraline-induced hepatotoxicity, based on preliminary glucose/galactose HepG2 results, and that future studies are needed on drug metabolism and CYP enzymes.
- Evident from the text: the study is in vitro only, using male rat primary hepatocytes and isolated rat liver mitochondria, with no in vivo liver injury model or human validation; parent drug versus metabolite contributions are not fully resolved, although SKF 525-A enhanced toxicity suggests the parent form is more toxic.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 0 Not valid · 21 Not checked · 45 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Cyclosporine A (CsA), a pseudosubstrate of CyPD (Lin and Lechleiter, 2002), keeps CyPD from interacting with MPTP then acts as an MPT inhibitor (Broekemeier et al., 1989).”
What the sources say
- Supportedcites Lin and Lechleiter, 2002 source
The Lin and Lechleiter citation is attached to the description of CsA as a CyPD pseudosubstrate, which the Abstract states. The subsequent claim that CsA prevents CyPD from interacting with the pore is attached to Broekemeier et al., not to this citation; Lin and Lechleiter’s Discussion describes that mechanism as an earlier model and reports evidence against it. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites Broekemeier et al., 1989 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“there are interindividual differences in the expression of drug metabolizing enzymes, affecting drug clearance and toxicity (Guo et al., 2011)”
What the sources say
- Supportedcites Guo et al., 2011 source
Guo et al. state in the discussion (p. 536) that interpatient differences in CYP3A4 activity are associated with differences in docetaxel clearance and toxicity. The section on interindividual variability also identifies differences in enzyme expression as a contributor to adverse drug reactions. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The mitochondrial inner membrane permeability transition (MPT) is one of main changes in mitochondria that leads to cell death (Al-Nasser and Crompton, 1986; Hunter and Haworth, 1979).”
What the sources say
- Partly supportedcites Al-Nasser and Crompton, 1986 sourceExperimental — accuracy not yet measured
The Introduction (page not available in our copy) links excess mitochondrial Ca2+ to impaired energy production that may ultimately lead to cell death, and describes Ca2+-induced inner-membrane permeabilization. It does not establish that permeability transition itself is a main change leading to cell death; the proposed link is more tentative than the citing sentence suggests. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites Hunter and Haworth, 1979 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the highest concentration (100μM) used in the study, ANT inhibition was approximately 40% (Fig. 5).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In mitochondria isolated from rat liver, sertraline uncoupled mitochondrial oxidative phosphorylation and inhibited the activities of oxidative phosphorylation complexes I and V.”
- Also stated in: § RESULTS · plain
“Sertraline Uncouples Oxidative Phosphorylation in Isolated Liver Mitochondria”
- Also stated in: § RESULTS · hedged
“Our results indicate that sertraline inhibited mitochondrial function by uncoupling oxidative phosphorylation (stimulating state 4, decreasing ADP/O) and inhibiting the activity of complex (inhibited state 3).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS · plain
42 more claims
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 15
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Since the toxic concentration of sertraline in our study started at 37.5μM, which is close to 100 times of reported Cmax of sertraline (~74μM), the concentrations used in our study were meaningful.”
Reported 100 · recomputed 50.675676
Citations
Cites
Chapter 4 Preparation of Isolated Rat Liver Cells
Seglen, P. O. (1976) · Methods in Cell Biology · doi:10.1016/s0091-679x(08)61797-5 · Cited by 5,310
Mitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598 · cited 1×
“Changes of the MPT pore cause mitochondrial swelling and uncoupling of oxidative phosphorylation, leading to interrupted ATP generation and further inducing cytotoxicity (Kroemer et al., 2007).”
BackgroundThe mitochondrial permeability transition pore and its role in cell death
CROMPTON, M. (1999) · Biochemical Journal · doi:10.1042/bj3410233 · Cited by 2,432 · cited 1×
“ANT, also as known as ADP/ATP antiporter (imports ADP to the matrix and exports ATP to the cytosol) which is located in the mitochondrial inner membrane, is a critical structural component of the pore (Crompton, 1999).”
BackgroundLee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Organelle isolation: functional mitochondria from mouse liver, muscle and cultured filroblasts
Frezza, C., Cipolat, S., & Scorrano, L. (2007) · Nature Protocols · doi:10.1038/nprot.2006.478 · Cited by 1,188 · cited 1×
“, Norfolk, England) following the method described by Frezza et al. (2007). For each reaction, mitochondria at a protein concentration of 1.”
MethodAn enzyme-release assay for natural cytotoxicity
Korzeniewski, C., & Callewaert, D. M. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90438-6 · Cited by 1,076
CYTOCHEMICAL STUDIES OF MAMMALIAN TISSUES
Hogeboom, G. H., Schneider, W. C., & Pallade, G. E. (1948) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52749-1 · Cited by 980
The Ca2+-induced membrane transition in mitochondria
Hunter, D. R., & Haworth, R. A. (1979) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(79)90371-0 · Cited by 856
The Ca2+-induced membrane transition in mitochondria
Haworth, R. A., & Hunter, D. R. (1979) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(79)90372-2 · Cited by 793
Broekemeier, K. M., Dempsey, M. E., & Pfeiffer, D. R. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83116-7 · Cited by 699 · cited 1×
“Cyclosporine A (CsA), a pseudosubstrate of CyPD (Lin and Lechleiter, 2002), keeps CyPD from interacting with MPTP then acts as an MPT inhibitor (Broekemeier et al., 1989).”
BackgroundMarroquin, L. D., Hynes, J., Dykens, J. A., Jamieson, J. D., & Will, Y. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm052 · Cited by 628
Cellular Imaging Predictions of Clinical Drug-Induced Liver Injury
Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., & de Graaf, D. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn109 · Cited by 492
The Ca2+-induced membrane transition in mitochondria
Hunter, D. R., & Haworth, R. A. (1979) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(79)90373-4 · Cited by 459
Hepatic Dysfunction Associated with Troglitazone
Watkins, P. B., & Whitcomb, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381314 · Cited by 446
Clinical Pharmacokinetics of Sertraline
DeVane, C. L., Liston, H. L., & Markowitz, J. S. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241150-00002 · Cited by 404
Biochemical Assays of Respiratory Chain Complex Activity
Kirby, D. M., Thorburn, D. R., Turnbull, D. M., & Taylor, R. W. (2007) · Methods in Cell Biology · doi:10.1016/s0091-679x(06)80004-x · Cited by 384
Kreamer, B. L., Staecker, J. L., Sawada, N., Sattler, G. L., Hsia, M. T. S., & Pitot, H. C. (1986) · In Vitro Cellular & Developmental Biology · doi:10.1007/bf02623304 · Cited by 383
Guo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J.-L., Green, B., Deng, H., Kaput, J., & Ning, B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035873 · Cited by 348
Self-citationCYTOCHEMICAL STUDIES OF MAMMALIAN TISSUES
Hogeboom, G. H., & Schneider, W. C. (1950) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)56236-0 · Cited by 334
Labbe, G., Pessayre, D., & Fromenty, B. (2008) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00608.x · Cited by 317 · cited 1×
“xenobiotic-associated mitochondrial impairment (Labbe et al. 2008).”
Connern, C. P., & Halestrap, A. P. (1994) · Biochemical Journal · doi:10.1042/bj3020321 · Cited by 246 · cited 1×
“Besides ANT, cyclophilin D (CyPD), located in mitochondrial matrix, is another component important in assembling the MPTP (Connern and Halestrap, 1994).”
BackgroundThe mitochondrial ADP/ATP carrier: Structural, physiological and pathological aspects
Fiore, C., Trézéguet, V., Le Saux, A., Roux, P., Schwimmer, C., Dianoux, A. C., Noel, F., Lauquin, G. J.-M., Brandolin, G., & Vignais, P. V. (1998) · Biochimie · doi:10.1016/s0300-9084(98)80020-5 · Cited by 209
Tissue variation in the control of oxidative phosphorylation: Implication for mitochondrial diseases
ROSSIGNOL, R., LETELLIER, T., MALGAT, M., ROCHER, C., & MAZAT, J.-P. (2000) · Biochemical Journal · doi:10.1042/bj3470045 · Cited by 202 · cited 1×
“of ANT, to ensure that the ADP/ATP exchange was mediated by the ADP/ATP carrier (Atlante et al., 2003; Rossignol et al., 2000; Wanders et al., 1984).”
BackgroundDykens, J. A., Jamieson, J. D., Marroquin, L. D., Nadanaciva, S., Xu, J. J., Dunn, M. C., Smith, A. R., & Will, Y. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn056 · Cited by 195
Mitochondrial membrane permeability transition and cell death
Tsujimoto, Y., Nakagawa, T., & Shimizu, S. (2006) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2006.03.017 · Cited by 188 · cited 1×
“The MPT pore is a protein pore formed by structural molecules such as voltage-dependent anion channel, ANT, and cyclophilin D (CyPD) (Tsujimoto et al., 2006).”
BackgroundMitochondrial Targeted Cyclophilin D Protects Cells from Cell Death by Peptidyl Prolyl Isomerization
Lin, D.-T., & Lechleiter, J. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112035200 · Cited by 181
Ong, M. M. K., Latchoumycandane, C., & Boelsterli, U. A. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfl180 · Cited by 178
The reversible Ca2+-induced permeabilization of rat liver mitochondria
Al-Nasser, I., & Crompton, M. (1986) · Biochemical Journal · doi:10.1042/bj2390019 · Cited by 175
The role of mitochondria in pharmacotoxicology: A reevaluation of an old, newly emerging topic
Scatena, R., Bottoni, P., Botta, G., Martorana, G. E., & Giardina, B. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00314.2006 · Cited by 163 · cited 2×
“The mechanisms of drug-induced mitochondrial dysfunction include uncoupling of electron transport from ATP synthesis, inhibition of mitochondrial complexes, opening of the MPT pore, and inhibition of mitochondrial DNA polymerase (Dykens et al., 2007; Scatena et al., 2007).”
BackgroundPharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
Wang, J., Liu, Z., Wang, W., Chen, X., Shu, Y., He, N., & Zhou, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116513 · Cited by 147 · cited 1×
“Although the contributions of the individual CYP 450s need to be detailed, CYP2C19 will be a first candidate to be studied because in a pharmacokinetics study it was reported that poor CYP2C19 metabolizers had a higher level of sertraline than normal metabolizers (Wang et al., 2001).”
BackgroundClinical implications of the pharmacology of sertraline
WARRINGTON, S. J. (1991) · International Clinical Psychopharmacology · doi:10.1097/00004850-199112002-00004 · Cited by 119
Effects of Troglitazone on HepG2 Viability and Mitochondrial Function
Tirmenstein, M. A. (2002) · Toxicological Sciences · doi:10.1093/toxsci/69.1.131 · Cited by 110
Masubuchi, Y., Kano, S., & Horie, T. (2006) · Toxicology · doi:10.1016/j.tox.2006.02.017 · Cited by 100
Strategies to reduce late-stage drug attrition due to mitochondrial toxicity
Dykens, J. A., Marroquin, L. D., & Will, Y. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.2.161 · Cited by 95
WANDERS, R. J. A., GROEN, A. K., VAN ROERMUND, C. W. T., & TAGER, J. M. (1984) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1984.tb08303.x · Cited by 93 · cited 1×
“of ANT, to ensure that the ADP/ATP exchange was mediated by the ADP/ATP carrier (Atlante et al., 2003; Rossignol et al., 2000; Wanders et al., 1984).”
BackgroundKlingenberg, M., & Buchholz, M. (1973) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1973.tb03067.x · Cited by 84
Saletu, B., Gr�nberger, J., & Linzmayer, L. (1986) · Journal of Neural Transmission · doi:10.1007/bf01243351 · Cited by 78 · cited 1×
“74lM) (Saletu et al., 1986), and plasma concentrations were higher in young females and in elderly patients of both sexes (Warrington, 1991).”
BackgroundGuo, L., Zhang, L., Sun, Y. A., Muskhelishvili, L., Blann, E., Dial, S. L., Shi, L. M., Schroth, G. P., & Dragan, Y. P. (2006) · Molecular Diversity · doi:10.1007/s11030-006-9038-0 · Cited by 77
Self-citationGuo, L., Fang, H., Collins, J., Fan, X.-H., Dial, S., Wong, A., Mehta, K., Blann, E., Shi, L., Tong, W., et al. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-s2-s18 · Cited by 69
Self-citationIMAI, H., KOUMURA, T., NAKAJIMA, R., NOMURA, K., & NAKAGAWA, Y. (2003) · Biochemical Journal · doi:10.1042/bj20021342 · Cited by 67 · cited 1×
“whereas an agonist of ANT, atractyloside (ATR), opens the MPTP (Imai et al. 2003).”
BackgroundMasubuchi, Y., Yamada, S., & Horie, T. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00163-x · Cited by 53 · cited 1×
“2), it is clear that irrespective of the substrate used (glutamate/malate for complex I or succinate for complex II), state 4 respiration was stimulated, which characterized sertraline as an uncoupler of mitochondrial oxidative phosphorylation (Masubuchi et al., 1999).”
BackgroundAtlante, A., De Bari, L., Bobba, A., Marra, E., Calissano, P., & Passarella, S. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01863.x · Cited by 45
A critical appraisal of the association between energy charge and cell damage
Kristensen, S. R. (1989) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(89)90108-0 · Cited by 43
Persky, S. E., & Reinus, J. F. (2003) · Digestive Diseases and Sciences · doi:10.1023/a:1023007831047 · Cited by 41
Fulminant Chemical Hepatitis Possibly Associated with Donepezil and Sertraline Therapy
Verrico, M. M., Nace, D. A., & Towers, A. L. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb03879.x · Cited by 38
Atlante, A., Bobba, A., Lidia de, B. A. R. I., Fontana, F., Calissano, P., Marra, E., & Passarella, S. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03820.x · Cited by 37
Symptomatic liver injury probably related to sertraline.
Hautekèete, M., Colle, I. O., Vlierberghe, H. V., & Elewaut, A. (1998) · PubMed · Cited by 34
Sertraline hepatotoxicity: Report of a case and review of the literature
Collados, V., Hallal, H., & Andrade, R. J. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1192-7 · Cited by 33
Acute fatal hepatitis related to sertraline
Fartoux-Heymann, L., Hézode, C., Zafrani, E. S., Dhumeaux, D., & Mallat, A. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00159-3 · Cited by 32 · cited 1×
“Extensive hepatocyte necrosis, with formation of bridges linking portal tracts together and to terminal hepatic venules, was found in one fatal case (Fartoux-Heymann et al., 2001); another case of severe hepatitis was due to a hypersensitivity reaction cholestasis that appeared 2 months after taking sertraline with a…”
BackgroundPreclinical toxicological evaluation of sertraline hydrochloride
Davies, T. S., & Kluwe, W. M. (1998) · Drug and Chemical Toxicology · doi:10.3109/01480549809002220 · Cited by 30
Preclinical Toxicological Evaluation of Sertraline Hydrochloride
Davies, T. S., & Klowe, W. M. (1998) · Drug and Chemical Toxicology · doi:10.3109/01480549809011645 · Cited by 29
Acute Liver Damage Possibly Related to Sertraline and Venlafaxine Ingestion
Kim, K. Y., Hwang, W. S., & Narendran, R. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18155 · Cited by 20
Drug efficacy, safety, and biologics discovery : emerging technologies and tools
Ekins, S., & Xu, J. J. (2009) · Medical Entomology and Zoology · Cited by 19
Biour, M., Poupon, R. Y., Grange, J., et al. (1988) · Gastroentérologie Clinique et Biologique · Cited by 15
Hepatotoxicidad asociada a sertralina
Collados Arroyo, V., Plaza Aniorte, J., Hallal, H., & Pérez-Cuadrado, E. (2008) · Farmacia Hospitalaria · doi:10.1016/s1130-6343(08)72814-9 · Cited by 9
[Hepatotoxicity of drugs. An updated bibliographic database of liver diseases and related drugs].
Biour, M., Poupon, R. Y., Grangé, J., et al. (1992) · PubMed · Cited by 9
[Acute cholestatic hepatitis probably caused by sertraline].
Navarro, J. L. G. (2001) · PubMed · Cited by 8
Cellular Systems Biology Applied to Preclinical Safety Testing: A Case Study of CellCiphrTMProfiling
Vernetti, L., Irwin, W., Giuliano, K. A., Gough, A., Johnston, K., & Taylor, D. L. (2008) · Drug Efficacy, Safety, and Biologics Discovery · doi:10.1002/9780470431818.ch3 · Cited by 6
Mujer de mediana edad con prurito y patrón analítico de colestasis aguda
Matos, Y. M. (2002) · Medicina de Familia SEMERGEN · doi:10.1016/s1138-3593(02)74046-x · Cited by 2
Research works printed but not linked: 2
- Galán Navarro, 2001, Hepatitis aguda colestásica probablemente causada por sertralina, Rev. Esp. Enferm. Dig., 93, 822
- Zoloft, 1997, Roering Division of Pfizer, Inc
Cited by
Alcocer-Gómez, E., de Miguel, M., Casas-Barquero, N., Núñez-Vasco, J., Sánchez-Alcazar, J. A., Fernández-Rodríguez, A., & Cordero, M. D. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.10.017 · Cited by 443
Czarny, P., Wigner, P., Galecki, P., & Sliwinski, T. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.036 · Cited by 310
“However, it should be mentioned that antidepressants can induce oxidative stress [Li et al. 2012, Moreno-Fernández et al. 2012, Hroudova and Fisar 2010, Alcocer-Gómez et al. 2014].”
BackgroundLindqvist, D., Wolkowitz, O. M., Picard, M., Ohlsson, L., Bersani, F. S., Fernström, J., Westrin, Å., Hough, C. M., Lin, J., Reus, V. I., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-017-0001-9 · Cited by 188
“, via inhibition of mitochondrial enzyme complexes [50], and uncoupling of oxidative phosphorylation [51].”
BackgroundA mitochondrial bioenergetic basis of depression
Klinedinst, N. J., & Regenold, W. T. (2014) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-014-9584-6 · Cited by 163
“Additionally, sertraline has been shown to cause mitochondrial dysfunction via ATP depletion, inhibition of oxidative phosphorylation complexes I and IV, and induction of Ca2+ mediated mitochondrial permeability transition (MPT) in liver mitochondria, which may contribute to the hepatotoxic effects of sertraline seen…”
BackgroundSong, B.-J., Akbar, M., Abdelmegeed, M. A., Byun, K., Lee, B., Yoon, S. K., & Hardwick, J. P. (2014) · Redox Biology · doi:10.1016/j.redox.2014.10.004 · Cited by 123
Metadata
- Authors
- Li, Y., Couch, L., Higuchi, M., Fang, J.-L., & Guo, L.
- Affiliations
- National Center for Toxicological Research (US)
- University of Arkansas for Medical Sciences (US)
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-03-02
- Volume
- 127
- Issue
- 2
- Pages
- 582-591
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- PMC
- PMC5736306
- OpenAlex
- W1994651650
- Cited by
- 120
- References
- 63
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 14 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 6 · 2018: 9 · 2017: 13 · 2016: 10 · 2015: 7 · 2014: 9 · 2013: 7 · 2012: 2
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Toxicological Sciences (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (FD999999)
- U.S. Food and Drug Administration
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- sertraline, selective serotonin reuptake inhibitors, hepatotoxicity, mitochondrial dysfunction, mitochondrial permeability transition, adenine nucleotide translocase, bongkrekic acid, mitochondrial uncoupling, complex I, ATP synthase, ATP depletion, lactate dehydrogenase leakage, drug-induced liver injury
- MeSH terms
- Mitochondrial Permeability Transition Pore, Mitochondrial ADP, ATP Translocases, Adenosine Triphosphate, Animals, Antidepressive Agents, Bongkrekic Acid, Cells, Cultured, Dose-Response Relationship, Drug, Energy Metabolism, L-Lactate Dehydrogenase, Male, Mitochondria, Liver, Oxidative Phosphorylation, Time Factors, Cyclosporine, Rats, Sprague-Dawley, Selective Serotonin Reuptake Inhibitors, Risk Assessment, Sertraline, Hepatocytes, Mitochondrial Diseases, Mitochondrial Membrane Transport Proteins, Electron Transport Chain Complex Proteins, Rats, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.